474 related articles for article (PubMed ID: 25520132)
1. Preclinical activity of lobaplatin as a single agent and in combination with taxanes for ovarian carcinoma cells.
Sun X; Lou LG; Sui DH; Wu XH
Asian Pac J Cancer Prev; 2014; 15(22):9939-43. PubMed ID: 25520132
[TBL] [Abstract][Full Text] [Related]
2. Antitumor activity of lobaplatin alone or in combination with antitubulin agents in non-small-cell lung cancer.
Xie CY; Xu YP; Jin W; Lou LG
Anticancer Drugs; 2012 Aug; 23(7):698-705. PubMed ID: 22441567
[TBL] [Abstract][Full Text] [Related]
3. Preclinical activity of a new platinum analogue, lobaplatin, in cisplatin-sensitive and -resistant human testicular, ovarian, and gastric carcinoma cell lines.
Harstrick A; Bokemeyer C; Scharnofkse M; Hapke G; Reile D; Schmoll HJ
Cancer Chemother Pharmacol; 1993; 33(1):43-7. PubMed ID: 8269588
[TBL] [Abstract][Full Text] [Related]
4. Effects of lobaplatin as a single agent and in combination with TRAIL on the growth of triple-negative p53-mutated breast cancers in vitro.
Engel JB; Martens T; Hahne JC; Häusler SF; Krockenberger M; Segerer S; Djakovic A; Meyer S; Dietl J; Wischhusen J; Honig A
Anticancer Drugs; 2012 Apr; 23(4):426-36. PubMed ID: 22314264
[TBL] [Abstract][Full Text] [Related]
5. The antitumor effect of lobaplatin against Ishikawa endometrial cancer cells in vitro and in vivo.
He J; Zhang H
Biomed Pharmacother; 2019 Jun; 114():108762. PubMed ID: 30925454
[TBL] [Abstract][Full Text] [Related]
6. Rapamycin enhanced the antitumor efficacy of oxaliplatin in cisplatin-resistant ovarian cancer cells A2780cis both in vitro and in vivo.
Liu J; Zhang L; Zhang X; Xing X
J Chemother; 2015; 27(6):358-64. PubMed ID: 25976336
[TBL] [Abstract][Full Text] [Related]
7. Novel expression of CD11b in epithelial ovarian cancer: Potential therapeutic target.
Saed GM; Fletcher NM; Diamond MP; Morris RT; Gomez-Lopez N; Memaj I
Gynecol Oncol; 2018 Mar; 148(3):567-575. PubMed ID: 29329880
[TBL] [Abstract][Full Text] [Related]
8. [Clinical study on chemotherapy of lobaplatin combined with docetaxel in patients with relapsed ovarian cancer].
Li X; Li Y
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2014 Nov; 39(11):1131-6. PubMed ID: 25432369
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of Lobaplatin against esophageal squamous cell carcinoma through caspase-dependent apoptosis and increasing the Bax/Bcl-2 ratio.
Du L; Fei Z; Song S; Wei N
Biomed Pharmacother; 2017 Nov; 95():447-452. PubMed ID: 28865364
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the therapeutic effects of lobaplatin and carboplatin on retinoblastoma in vitro and in vivo.
Zhou Z; Jiang H; Xia J; Zhang J
Int J Oncol; 2020 Sep; 57(3):697-706. PubMed ID: 32582992
[TBL] [Abstract][Full Text] [Related]
11. Costunolide induces apoptosis in platinum-resistant human ovarian cancer cells by generating reactive oxygen species.
Yang YI; Kim JH; Lee KT; Choi JH
Gynecol Oncol; 2011 Dec; 123(3):588-96. PubMed ID: 21945308
[TBL] [Abstract][Full Text] [Related]
12. Drug interactions of 5-fluorouracil with either cisplatin or lobaplatin--a new, clinically active platinum analog in established human cancer cell lines.
Harstrick A; Vanhoefer U; Heidemann A; Druyen H; Wilke H; Seeber S
Anticancer Drugs; 1997 Apr; 8(4):391-5. PubMed ID: 9180394
[TBL] [Abstract][Full Text] [Related]
13. Lobaplatin inhibits prostate cancer progression in part by impairing AR and ERG signal.
Chen L; Cao H; Yu C; Feng Y
Fundam Clin Pharmacol; 2018 Oct; 32(5):548-557. PubMed ID: 29733466
[TBL] [Abstract][Full Text] [Related]
14. Hyperthermia enhances the cytotoxicity and platinum-DNA adduct formation of lobaplatin and oxaliplatin in cultured SW 1573 cells.
Rietbroek RC; van de Vaart PJ; Haveman J; Blommaert FA; Geerdink A; Bakker PJ; Veenhof CH
J Cancer Res Clin Oncol; 1997; 123(1):6-12. PubMed ID: 8996534
[TBL] [Abstract][Full Text] [Related]
15. Preclinical antitumor evaluation of bis-acetato-ammine-dichloro-cyclohexylamine platinum(IV): an orally active platinum drug.
Kelland LR; Abel G; McKeage MJ; Jones M; Goddard PM; Valenti M; Murrer BA; Harrap KR
Cancer Res; 1993 Jun; 53(11):2581-6. PubMed ID: 8388318
[TBL] [Abstract][Full Text] [Related]
16. Lobaplatin suppresses proliferation and induces apoptosis in the human colorectal carcinoma cell Line LOVO in vitro.
Dai HY; Liu L; Qin SK; He XM; Li SY
Biomed Pharmacother; 2011 Jun; 65(3):137-41. PubMed ID: 21612887
[TBL] [Abstract][Full Text] [Related]
17. Lobaplatin induces pyroptosis through regulating cIAP1/2, Ripoptosome and ROS in nasopharyngeal carcinoma.
Chen Z; Xu G; Wu D; Wu S; Gong L; Li Z; Luo G; Hu J; Chen J; Huang X; Chen C; Jiang Z; Li X
Biochem Pharmacol; 2020 Jul; 177():114023. PubMed ID: 32413426
[TBL] [Abstract][Full Text] [Related]
18. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor.
Ciardiello F; Caputo R; Bianco R; Damiano V; Pomatico G; De Placido S; Bianco AR; Tortora G
Clin Cancer Res; 2000 May; 6(5):2053-63. PubMed ID: 10815932
[TBL] [Abstract][Full Text] [Related]
19. A trial of lobaplatin (D-19466) in platinum-resistant ovarian cancer.
Kavanagh JJ; Edwards CL; Freedman RS; Finnegan MB; Balat O; Tresukosol D; Burk K; Loechner S; Hord M; Franklin JL
Gynecol Oncol; 1995 Jul; 58(1):106-9. PubMed ID: 7789874
[TBL] [Abstract][Full Text] [Related]
20. Preclinical antitumor activity of the oral platinum analog satraplatin.
Wosikowski K; Lamphere L; Unteregger G; Jung V; Kaplan F; Xu JP; Rattel B; Caligiuri M
Cancer Chemother Pharmacol; 2007 Sep; 60(4):589-600. PubMed ID: 17541592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
